Secondary Progressive Multiple Sclerosis Clinical Trials
3 recruiting trials for Secondary Progressive Multiple Sclerosis. Eligibility criteria explained in plain English.
TrialFinderData lists 3 Secondary Progressive Multiple Sclerosis clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 2 is the largest group at 33% (1 studies); the largest phase groups are Phase 2: 1, Phase 3: 1, Phase 1: 1.
Research is led by Tiziana Life Sciences LTD (1), Zenas BioPharma (USA), LLC (1), Queen Mary University of London (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Placebo (other, 2 trials), followed by Foralumab, Orelabrutinib.
Track Secondary Progressive Multiple Sclerosis trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Foralumab is a human anti-CD3 monoclonal antibody being developed for the treatment of autoimmune and inflammatory diseases. The goal of this Phase 2a, randomized, double-blind...
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of...
SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
The study seeks to investigate safety and efficacy of ixazomib (NINLARO), a proteasome inhibitor, in multiple sclerosis (MS). Participants will receive either ixazomib capsules or...
Explore Other Conditions
Frequently Asked Questions
There are currently 3 clinical trials for Secondary Progressive Multiple Sclerosis, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Secondary Progressive Multiple Sclerosis, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Secondary Progressive Multiple Sclerosis, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.